(Total Views: 379)
Posted On: 04/16/2019 11:13:25 AM
Post# of 72440
so, the emphasis will be on keveterin now and Bilatricin will be moved the back burner? opinions appreciated!
i guess this answers my question:
As we continue to advance the clinical development of our Brilacidin programs in Oral Mucositis and Inflammatory Bowel Disease, the Company concurrently plans to devote resources to Kevetrin, including completing remaining bridging toxicology work toward developing Kevetrin in oral form. An orally-delivered Kevetrin would likely enhance the therapeutic benefits based on its pharmacokinetics, and broaden its market potential by meeting cancer patient’s strong preference for oral meds.
also-very interesting:
The FDA has awarded Orphan Drug status for Kevetrin in ovarian cancer, pancreatic cancer, and retinoblastoma, qualifying it for developmental incentives and a potential extra 7 years of market exclusivity upon drug approval. The FDA also has granted Kevetrin Rare Pediatric Disease designation for childhood retinoblastoma.
here some thoughts of mine, which helps me to be patient and stay long on ipix: years ago i bought 1k shares of tech-and then i did not buy any more... for 10 yrs. tech stayed right at $1.10 pps -and then it ran from there to 13pps in about 9 mos or so... then it ran-about 2 yrs. later to 40pps and it split 2 for 1 and then about 2 yrs. later it ran to $130pps... and split 2 for 1(forward) and is now trading at 200+ pps ...and pays a dividend!(i was not patient-sold tech for $2.65-super ouch!)
summary: some have been in ipix for 10 years? well, it appears things can start heating up...hang in there all longs!!!
i guess this answers my question:
As we continue to advance the clinical development of our Brilacidin programs in Oral Mucositis and Inflammatory Bowel Disease, the Company concurrently plans to devote resources to Kevetrin, including completing remaining bridging toxicology work toward developing Kevetrin in oral form. An orally-delivered Kevetrin would likely enhance the therapeutic benefits based on its pharmacokinetics, and broaden its market potential by meeting cancer patient’s strong preference for oral meds.
also-very interesting:
The FDA has awarded Orphan Drug status for Kevetrin in ovarian cancer, pancreatic cancer, and retinoblastoma, qualifying it for developmental incentives and a potential extra 7 years of market exclusivity upon drug approval. The FDA also has granted Kevetrin Rare Pediatric Disease designation for childhood retinoblastoma.
here some thoughts of mine, which helps me to be patient and stay long on ipix: years ago i bought 1k shares of tech-and then i did not buy any more... for 10 yrs. tech stayed right at $1.10 pps -and then it ran from there to 13pps in about 9 mos or so... then it ran-about 2 yrs. later to 40pps and it split 2 for 1 and then about 2 yrs. later it ran to $130pps... and split 2 for 1(forward) and is now trading at 200+ pps ...and pays a dividend!(i was not patient-sold tech for $2.65-super ouch!)
summary: some have been in ipix for 10 years? well, it appears things can start heating up...hang in there all longs!!!
(0)
(0)Scroll down for more posts ▼
